Vanguard Group Inc. trimmed its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,732,204 shares of the company's stock after selling 106,699 shares during the quarter. Vanguard Group Inc. owned approximately 5.53% of Cryoport worth $21,257,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Avanza Fonder AB acquired a new stake in Cryoport during the 4th quarter valued at $64,000. Olympiad Research LP bought a new position in shares of Cryoport in the fourth quarter valued at about $103,000. Fox Run Management L.L.C. acquired a new position in Cryoport during the 4th quarter worth about $111,000. Heritage Investors Management Corp acquired a new stake in Cryoport in the 4th quarter valued at about $122,000. Finally, NRI Wealth Management LC bought a new position in shares of Cryoport in the fourth quarter worth about $149,000. Institutional investors and hedge funds own 92.90% of the company's stock.
Insiders Place Their Bets
In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last three months. 10.10% of the stock is currently owned by corporate insiders.
Cryoport Stock Down 1.1 %
NASDAQ CYRX traded down $0.06 on Friday, reaching $5.55. The company had a trading volume of 406,571 shares, compared to its average volume of 544,600. The company's fifty day moving average is $5.99 and its 200-day moving average is $7.00. The firm has a market capitalization of $277.00 million, a price-to-earnings ratio of -1.64 and a beta of 1.81. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $17.41.
Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). The firm had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the previous year, the business posted ($0.29) earnings per share. On average, research analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. Roth Mkm reissued a "buy" rating and issued a $15.00 price target on shares of Cryoport in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $11.00 target price on shares of Cryoport in a research report on Wednesday. Guggenheim reiterated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday. Finally, UBS Group boosted their price objective on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $11.67.
Check Out Our Latest Report on Cryoport
Cryoport Profile
(
Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Articles
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
